{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:33:39Z","timestamp":1787981619996,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA180803"],"award-info":[{"award-number":["CA180803"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA21765"],"award-info":[{"award-number":["P30CA21765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180899"],"award-info":[{"award-number":["U10CA180899"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180886"],"award-info":[{"award-number":["U10CA180886"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018762","name":"Seattle Children's Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018762","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kat's Crew Guild, Sarcoma Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00280-022-04397-4","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T03:02:42Z","timestamp":1643252562000},"page":"551-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children\u2019s Oncology Group and NRG Oncology study ARST1321"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-2924","authenticated-orcid":false,"given":"J.","family":"Gartrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Panetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ostrenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Scharschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Spunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"2","key":"4397_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijrobp.2015.02.007","volume":"92","author":"TV Waxweiler","year":"2015","unstructured":"Waxweiler TV et al (2015) Non-rhabdomyosarcoma soft tissue sarcomas in children: a surveillance, epidemiology, and end results analysis validating COG risk stratifications. Int J Radiat Oncol Biol Phys 92(2):339\u2013348","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4397_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(19)30672-2","volume":"21","author":"SL Spunt","year":"2020","unstructured":"Spunt SL et al (2020) A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children\u2019s Oncology Group prospective study. Lancet Oncol 21(1):145\u2013161","journal-title":"Lancet Oncol"},{"issue":"12","key":"4397_CR3","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI et al (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15(12):4220\u20134227","journal-title":"Clin Cancer Res"},{"issue":"24","key":"4397_CR4","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","volume":"31","author":"JL Glade Bender","year":"2013","unstructured":"Glade Bender JL et al (2013) Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children\u2019s oncology group phase I consortium report. J Clin Oncol 31(24):3034\u20133043","journal-title":"J Clin Oncol"},{"issue":"9829","key":"4397_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879\u20131886","journal-title":"Lancet"},{"key":"4397_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.06.016","volume":"137","author":"AC Hirbe","year":"2020","unstructured":"Hirbe AC et al (2020) A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer 137:1\u20139","journal-title":"Eur J Cancer"},{"issue":"4","key":"4397_CR7","first-page":"443","volume":"71","author":"SV Keisner","year":"2011","unstructured":"Keisner SV, Shah SR (2011) Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71(4):443\u2013454","journal-title":"Drugs"},{"issue":"9","key":"4397_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","volume":"56","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB et al (2017) Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet 56(9):987\u2013997","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4397_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/1535-7163.MCT-09-0960","volume":"9","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K et al (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4):996\u20131006","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4397_CR10","doi-asserted-by":"publisher","first-page":"233.e7","DOI":"10.1016\/j.urology.2011.02.041","volume":"78","author":"Y Li","year":"2011","unstructured":"Li Y et al (2011) Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology 78(1):233.e7\u201313","journal-title":"Urology"},{"issue":"17","key":"4397_CR11","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1158\/1078-0432.CCR-11-0078","volume":"17","author":"S Kumar","year":"2011","unstructured":"Kumar S et al (2011) Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17(17):5656\u20135667","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4397_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","volume":"21","author":"AR Weiss","year":"2020","unstructured":"Weiss AR et al (2020) Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol 21(8):1110\u20131122","journal-title":"Lancet Oncol"},{"issue":"3","key":"4397_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2174\/092986711794839197","volume":"18","author":"SM He","year":"2011","unstructured":"He SM et al (2011) Structural and functional properties of human multidrug resistance protein 1 (MRP1\/ABCC1). Curr Med Chem 18(3):439\u2013481","journal-title":"Curr Med Chem"},{"issue":"1","key":"4397_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1124\/mol.53.1.141","volume":"53","author":"C Marbeuf-Gueye","year":"1998","unstructured":"Marbeuf-Gueye C et al (1998) Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol 53(1):141\u2013147","journal-title":"Mol Pharmacol"},{"issue":"2","key":"4397_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/dmd.108.024612","volume":"37","author":"S Shukla","year":"2009","unstructured":"Shukla S et al (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37(2):359\u2013365","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"4397_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","volume":"78","author":"AK Tiwari","year":"2009","unstructured":"Tiwari AK et al (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters. Biochem Pharmacol 78(2):153\u2013161","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"4397_CR17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/138920010792927316","volume":"11","author":"XK Wang","year":"2010","unstructured":"Wang XK, Fu LW (2010) Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins. Curr Drug Metab 11(7):618\u2013628","journal-title":"Curr Drug Metab"},{"issue":"10","key":"4397_CR18","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1021\/jm300212s","volume":"55","author":"M Karlgren","year":"2012","unstructured":"Karlgren M et al (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55(10):4740\u20134763","journal-title":"J Med Chem"},{"issue":"7","key":"4397_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ijc.28797","volume":"135","author":"S Durmus","year":"2014","unstructured":"Durmus S et al (2014) In vivo disposition of doxorubicin is affected by mouse Oatp1a\/1b and human OATP1A\/1B transporters. Int J Cancer 135(7):1700\u20131710","journal-title":"Int J Cancer"},{"issue":"9","key":"4397_CR20","first-page":"856","volume":"12","author":"DA Garrison","year":"2020","unstructured":"Garrison DA et al (2020) Role of OATP1B1 and OATP1B3 in drug\u2013drug interactions mediated by tyrosine kinase inhibitors. Pharm 12(9):856","journal-title":"Pharm"},{"issue":"2","key":"4397_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1006\/abio.1998.2943","volume":"266","author":"P de Bruijn","year":"1999","unstructured":"de Bruijn P et al (1999) Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 266(2):216\u2013221","journal-title":"Anal Biochem"},{"key":"4397_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jchromb.2012.12.012","volume":"915\u2013916","author":"C Sottani","year":"2013","unstructured":"Sottani C et al (2013) Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC-MS\/MS in human plasma of HCC patients treated with TACE. J Chromatogr B Analyt Technol Biomed Life Sci 915\u2013916:71\u201378","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"4397_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00280-008-0854-z","volume":"64","author":"PA Thompson","year":"2009","unstructured":"Thompson PA et al (2009) Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 64(2):243\u2013251","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4397_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00280-013-2069-1","volume":"71","author":"NE Kontny","year":"2013","unstructured":"Kontny NE et al (2013) Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemother Pharmacol 71(3):749\u2013763","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"4397_CR25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s40262-015-0272-4","volume":"54","author":"S V\u00f6ller","year":"2015","unstructured":"V\u00f6ller S et al (2015) Age-dependent pharmacokinetics of doxorubicin in children with cancer. Clin Pharmacokinet 54(11):1139\u20131149","journal-title":"Clin Pharmacokinet"},{"key":"4397_CR26","doi-asserted-by":"publisher","first-page":"648407","DOI":"10.3389\/fphar.2021.648407","volume":"12","author":"H Xiao","year":"2021","unstructured":"Xiao H et al (2021) Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol 12:648407","journal-title":"Front Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04397-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04397-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04397-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T18:10:07Z","timestamp":1648231807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04397-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4397"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04397-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JG reports a Grant from Eli Lilly and Company outside the submitted work. ARW reports travel reimbursement from SpringWorks Therapeutics and paid consulting for BioAtla outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}